# US 2016/0237466 A1 · Multiple Proteases Deficient Filamentous Fungal Cells and Methods of Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0237466 A1
- Document ID: US20160237466A1
- Status: Published application
- Kind: A1
- Application number: 14/903,673
- Filed: 2014-07-10
- Published: 2016-08-18
- Earliest claimed: 2013-07-10
- Assignees: Glykos Finland Oy
- Applicants: Novartis AG; Glykos Finland Oy
- Inventors: Christopher Landowski; Anne Huuskonen; Ann Westerholm-Parvinen; Markku Saloheimo; Anne Kanerva; Jukka Hiltunen
- Web page: https://patentgrep.com/patent/US20160237466A1

## CPC

- C12P 21/00: Preparation of peptides or proteins (single cell protein C12N1/00)
- C12N 9/1051: {Hexosyltransferases (2.4.1)}
- C12N 9/14: Hydrolases (3)
- C12N 9/48: acting on peptide bonds (3.4)
- C12N 9/485: {Exopeptidases (3.4.11-3.4.19)}
- C12N 9/58: derived from fungi
- C12N 15/80: for fungi
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C12Y 204/01258: Dolichyl-P-Man:Man5GlcNAc2-PP-dolichol alpha-1,3-mannosyltransferase (2.4.1.258)
- C12Y 303/02006: Leukotriene-A4 hydrolase (3.3.2.6)
- C12Y 304/00: Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y 304/17021: Glutamate carboxypeptidase II (3.4.17.21)
- C12Y 304/21: Serine endopeptidases (3.4.21)
- C12Y 304/21062: Subtilisin (3.4.21.62)
- C12Y 304/21078: Granzyme A (3.4.21.78)
- C12Y 304/23: Aspartic endopeptidases (3.4.23)
- C12Y 304/23018: Aspergillopepsin I (3.4.23.18)
- C12Y 304/24: Metalloendopeptidases (3.4.24)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present disclosure relates to compositions and methods useful for the production of heterologous proteins in filamentous fungal cells.

## Claims

### Claim 1

A filamentous fungal cell comprising at least one endogenous protease having reduced or no protease activity, and a recombinant polynucleotide encoding a heterologous polypeptide, wherein the cell has reduced or no protease activity in one or more the following proteases: amp2, mp1, mp2, mp3, mp4, mp5, pep9, amp1, and sep1.

### Claim 2 (depends on 1)

The filamentous fungal cell of claim 1, wherein the fungal cell is a Trichoderma fungal cell, a Myceliophthora fungal cell, an Aspergillus fungal cell, a Neurospora fungal cell, a Penicillium cell, a Fusarium cell, or a Chrysosporium fungal cell.

### Claim 3 (depends on 1)

The filamentous fungal cell of claim 1, wherein the total protease activity is reduced to 40% or less, preferably 6% or less, of the total protease activity of the corresponding parental filamentous fungal cell in which the proteases do not have the reduced activity.

### Claim 4 (depends on 1)

The filamentous fungal cell of claim 1, wherein the cell further has reduced or no detectable protease activity in at least three or four proteases selected from the group consisting of pep1, pep2, pep3, pep4, pep5, pep8, pep11, pep12, tsp1, slp1, slp2, slp3, slp7, gap1, and gap2.

### Claim 5 (depends on 1)

The filamentous fungal cell of claim 1, wherein the cell has reduced or no protease activity in at least eight proteases, each of the genes encoding the eight proteases comprises a mutation that reduces or eliminates the corresponding protease activity, and the eight proteases are either:
a. pep1, slp1, gap1, gap2, pep4, pep3, pep5, amp2;
b. pep1, slp1, gap1, gap2, pep4, pep3, pep5, amp1;
c. pep1, slp1, gap1, gap2, pep4, pep3, pep5, sep1;
d. pep1, slp1, gap1, gap2, pep4, pep3, pep5, pep9; or
e. pep1, slp1, gap1, gap2, pep4, pep3, pep5, pep2.

### Claim 6 (depends on 1)

The filamentous fungal cell of claim 1, wherein the cell has reduced or no protease activity in at least nine proteases, each of the genes encoding the nine proteases comprises a mutation that reduces or eliminates the corresponding protease activity, and the nine proteases are pep1, slp1, gap1, gap2, pep4, pep3, pep5, pep2, and sep1.

### Claim 7 (depends on 1)

The filamentous fungal cell of claim 1, wherein the cell has reduced or no protease activity in at least ten proteases, each of the genes encoding the ten proteases comprises a mutation that reduces or eliminates the corresponding protease activity, and the ten proteases are pep1, slp1, gap1, gap2, pep4, pep3, pep5, pep2, sep1, and slp8.

### Claim 8 (depends on 1)

The filamentous fungal cell of claim 1, wherein the cell has reduced or no protease activity in at least eleven proteases, each of the genes encoding the eleven proteases comprises a mutation that reduces or eliminates the corresponding protease activity, and the eleven proteases are pep1, slp1, gap1, gap2, pep4, pep3, pep5, pep2, sep1, slp8, and amp2.

### Claim 9 (depends on 1)

The filamentous fungal cell of claim 1, wherein either,
(i) the cell has reduced or no protease activity in at least twelve proteases, each of the genes encoding the twelve proteases comprises a mutation that reduces or eliminates the corresponding protease activity, and the twelve proteases are pep1, slp1, gap1, gap2, pep4, pep3, pep5, pep2, sep1, slp8, amp2, and slp7;
(ii) the cell has reduced or no protease activity in at least thirteen proteases, each of the genes encoding the thirteen proteases comprises a mutation that reduces or eliminates the corresponding protease activity, and the thirteen proteases are either
pep1, tsp1, slp1, gap1, gap2, pep4, pep3, pep5, pep2, sep1, slp8, amp2, and pep9;
pep1, tsp1, slp1, gap1, gap2, pep4, pep3, pep5, pep2, sep1, slp8, amp2, and slp7; or,
pep1, tsp1, slp1, gap1, gap2, pep4, pep3, pep5, pep2, sep1, slp8, amp2, and slp3;
(iii) the cell has reduced or no protease activity in at least fourteen proteases, each of the genes encoding the fourteen proteases comprises a mutation that reduces or eliminates the corresponding protease activity, and the fourteen proteases are pep1, tsp1, slp1, gap1, gap2, pep4, pep3, pep5, pep2, sep1, slp8, amp2, pep9, and slp2; or,
(iv) the cell has reduced or no protease activity in at least fifteen proteases, each of the genes encoding the fifteen proteases comprises a mutation that reduces or eliminates the corresponding protease activity, and the fifteen proteases are either
pep1, tsp1, slp1, gap1, gap2, pep4, pep3, pep5, pep2, sep1, slp8, amp2, pep9, slp2, mp1; or,
pep1, tsp1, slp1, gap1, gap2, pep4, pep3, pep5, pep2, sep1, slp8, amp2, pep9, slp2, and mp5.

### Claim 10 (depends on 9)

The filamentous fungal cell according to claim 9, wherein the cell has reduced or no protease activity in at least sixteen, at least seventeen, at least eighteen, at least nineteen, or at least twenty or more proteases, further comprising at least one or more additional mutations, each additional mutation reduces or eliminates the corresponding additional protease activity, and said at least additional protease being selected from the group consisting of
an aspartic protease pep6, pep10, pep13, pep14, or pep16;
sip like protease slp57433, slp35726, slp60791, or slp109276;
gap like protease gap3 or gap4;
sedolisin like protease sed2, sed3, or sed5;
Group A protease selected from the group of protease65735, protease77577, protease81087, protease56920, protease122083, protease79485, protease120998, or protease611127;
Group B protease selected from the group of protease21659, protease58387, protease75159, protease56853, or protease64193;
Group C protease selected from the group of protease82452, protease80762, protease21668, protease81115, protease82141, protease23475;
Group D protease selected from the group of protease121890, protease22718, protease47127, protease61912, protease80843, protease66608, protease72612, protease40199; or
Group E protease selected from the group of protease22210, protease111694, protease82577.

### Claim 11 (depends on 1)

The filamentous fungal cell of claim 1, wherein the mammalian polypeptide is selected from the group consisting of an antibody and their antigen-binding fragments, a growth factor, an interferon, a cytokine, and an interleukin.

### Claim 12 (depends on 1)

The filamentous fungal cell of claim 1, wherein the fungal cell further comprises ALG3 having reduced activity.

### Claim 13 (depends on 12)

The filamentous fungal cell of claim 12, wherein the gene encoding ALG3 comprises a mutation that reduces or eliminates the corresponding activity.

### Claim 14 (depends on 1)

The filamentous fungal cell of claim 1, further comprising an N-acetylglucosaminyltransferase I catalytic domain, and, optionally, an N-acetylglucosaminyltransferase II catalytic domain.

### Claim 15 (depends on 1)

A method of improving stability of a polypeptide, comprising
a) providing the filamentous fungal cell of claim 1, and
b) culturing the cell such that the heterologous polypeptide is expressed, wherein the heterologous polypeptide exhibits increased stability compared to the heterologous polypeptide produced in a corresponding parental filamentous fungal cell in which the proteases do not have reduced activity.

### Claim 16 (depends on 1)

A method of making a heterologous polypeptide, comprising
a) providing the filamentous fungal cell of claim 1,
b) culturing the cell such that the heterologous polypeptide is expressed, and
c) purifying the heterologous polypeptide.

### Claim 17 (depends on 2)

The filamentous fungal cell of claim 2, wherein the total protease activity is reduced to 40% or less, preferably 6% or less, of the total protease activity of the corresponding parental filamentous fungal cell in which the proteases do not have the reduced activity.

### Claim 18 (depends on 2)

The filamentous fungal cell of claim 2, wherein the cell further has reduced or no detectable protease activity in at least three or four proteases selected from the group consisting of pep1, pep2, pep3, pep4, pep5, pep8, pep11, pep12, tsp1, slp1, slp2, slp3, slp7, gap1, and gap2.

### Claim 19 (depends on 3)

The filamentous fungal cell of claim 3, wherein the cell further has reduced or no detectable protease activity in at least three or four proteases selected from the group consisting of pep1, pep2, pep3, pep4, pep5, pep8, pep11, pep12, tsp1, slp1, slp2, slp3, slp7, gap1, and gap2.

### Claim 20 (depends on 2)

The filamentous fungal cell of claim 2, wherein the cell has reduced or no protease activity in at least eight proteases, each of the genes encoding the eight proteases comprises a mutation that reduces or eliminates the corresponding protease activity, and the eight proteases are either:
a. pep1, slp1, gap1, gap2, pep4, pep3, pep5, amp2;
b. pep1, slp1, gap1, gap2, pep4, pep3, pep5, amp1;
c. pep1, slp1, gap1, gap2, pep4, pep3, pep5, sep1;
d. pep1, slp1, gap1, gap2, pep4, pep3, pep5, pep9; or
e. pep1, slp1, gap1, gap2, pep4, pep3, pep5, pep2.
